2010
Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, Salomon JA on behalf of the ADVANCE Collaborative Group. Event rates, hospital utilization, and costs associated with major complications of diabetes: A multicountry comparative analysis.
PLOS Medicine 2010;7(2)e1000236.
Kengne A P, Patel A, Colagiuri S, Heller S, Hamet P, Marre M, Pan CY, Zoungas S, Grobbee D, Neal B, Chalmers J, Woodward M. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study.
Diabetelogia 2010;53(5):821-31.
2009
Turnbull F, Abraira C, Anderson R J, Byington R P, Chalmers J P, Duckworth W C, Evans G W, Gerstein H C, Holman R R, Moritz T E, Neal B C, Ninomiya T, Patel A A, Paul S K, Travert F, Woodward M for the Collaborators on Trial of Lowering Glucose (CONTROL) writing group. Intensive glucose control and macrovascular outcomes in type 2 diabetes.
Diabetelogia 2009. 52:2288-2298.
Zoungas S, Chalmers J, Patel A. Cardiovascular risk in Type 2 diabetes – reflecting on the ADVANCE Study.
European Endocrinology 2009;5(1):42-46. [IF: NA] Also published in:
US Endocrinology 2009;5(1):95-99.
de Galan BE, Zoungas S, Chalmers J, and al., for the ADVANCE Collaborative group. Cognitive function and risks of cardiovascular disease and hypoglycaemia in people with type 2 diabetes; the ADVANCE trial.
Diabetelogia [Epub ahead of print]
Abstract
Zoungas S, de Galan BE, Ninomiya T, and al., on behalf of the ADVANCE Collaborative Group. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE.
Diabetes Care, 2009 [Epub ahead of print]
Abstract
Beulens JWJ, Patel A, Vingerling JR, and al., on behalf of the AdRem project team and ADVANCE Management Committee (Chalmers J, Member ADVANCE Management Committee). Effects of blood pressure lowering and intensive glucose control on incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.
Diabetologia 2009 [Epub ahead of print]
Abstract
Brugts JJ, Ninomiya T, Boersma E, and al. The consistency of the treatment effect of an ACE-inhibitor-based treatment regimen in patients with vascular disease or high-risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS-trials comparing perindopril-indapamide versus placebo.
Eur. Heart J. 2009;30: 1385-394.
Abstract
Du X, Ninomiya T, de Galan B, and al., on behalf of the ADVANCE Collaborative Group. Risk of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and artrial fibrillation – results of the ADVANCE study.
Eur. Heart J. 2009;30:1128-1135.
Abstract
Joshi R, Galan B, Chalmers J, Perkovic V, Patel A. Routine blood pressure lowering and intensive glucose control in patients with type 2 diabetes: Results from the ADVANCE trial.
Exp. Rev. Endocrinol Metab. 2009 4(2), 111-118.
Kengne A-P, Czernichow S, Huxley Rm Grobbee D, and al. Blood pressure variables and cardiovascular risk: New findings from ADVANCE.
Hypertension 2009 54:399-404.
Abstract
Ninomiya T, Perkovic V, de Galan BE, and al., on behalf of the ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
J. Am. Soc. NephroL. 2009 20:1813-1821.
Abstract
Du X, Ninomiya T, de Galan B, and al., on behalf of the ADVANCE Collaborative Group. Risk of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and artrial fibrillation – results of the ADVANCE study.
Eur. Heart J. 2009;30:1128-1135.
Abstract
Patel A, Chalmers J, MacMahon S, Neal B. ADVANCE Blood pressure lowering in diabetes.
J. Clin. Hypert. 2008;11:108. (Letter).
Abstract
de Galan B, Perkovic V, Ninomiya T, and al., on behalf of the ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes.
J. Am. Soc. Nephrol. 2009;20:883-892.
Abstract
Patel A, MacMahon S, Chalmers J, on behalf of the ADVANCE Collaborative Group. Intensive Glucose Control in Type 2 Diabetes – the author’s reply.
N. Engl. J. Med. 2008;359:1519-1521. (Letter)
Chalmers J, Cooper M. UKPDS and the legacy effects.
N. Engl. J. Med. 2008;359:1618-1620. (Editorial)
Abstract
Chalmers J and Zanchetti A. Advances in the prevention of cardiovascular diseases in patients with diabetes.
J. Hypertens. 2008;26(Suppl 3) S1-S2.
Chalmers J, Joshi R, Kengne A-P, and al., on behalf of the ADVANCE Collaborative Group. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of evidence available in 2007.
J. Hypertens. 2008;26(Suppl 3) S21-S28.
Abstract
Chalmers J, Joshi R, Kengne A-P, MacMahon S. Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE.
J.Hypertens. Suppl. 2008; 26(Suppl2);S11-S15.
Abstract
ADVANCE Collaborative Group (Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Harrap S, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan B, Joshi R, Travert F.) Effects of intensive blood glucose control on vascular outcomes in patients with type 2 diabetes mellitus: results of the ADVANCE trial.
N. Engl. J. Med. 2008, 358:2560-2572.
Abstract
Chalmers J, Joshi R, Patel A. Advances in reducing the burden of vascular disease in type 2 diabetes.
Clin. Exp. Pharmacol. Physiol. 2008;35:434-437.
Abstract
Patel A, MacMahon S, Neal B, Billot L, Chalmers J, on behalf of the ADVANCE Collaborative Group. The ADVANCE Trial – the author’s reply.
Lancet 2008;371:25-26.
Chalmers J and Zanchetti A. Introduction : Hypertension in patients with diabetes: Can the treatment of macro and microvascular events be improved? Rationale of the ADVANCE Study. Editorial for the 5th Franco-Italian Meeting on Hypertension, Rome 2006.
J. Hypertens. 2007;25(Suppl1):S1-S2.
Glasziou P, Alexander J, Beller E, Clarke P and the ADVANCE Collaborative Group (Chalmers J, Chairman). Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.
Health Qual. Life Outcomes, 2007;5:21 doi 10.1186/1477-7525-5-21 [Epub ahead of print].
Abstract
Chalmers J, Kengne A-P, Joshi R, Perkovic V and Patel A. New insights from ADVANCE.
J. Hypertens.2007;25 (Suppl 1):S23-S30.
Abstract
Patel A, MacMahon S, Chalmers J, and al., on behalf of the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Lancet 2007;370:829-840.
Abstract
Monaghan H., Richens A., Colman S., and al. A randomised trial of the effects of an additional communication strategy on recruitment into a large-scale, multi-centre trial.
Contemp. Clin. Trials 2007;28:1-5.
Abstract
Stolk R.P., Vingerling J.R., Cruickshank J.K., and al, on behalf of the AdRem project team and ADVANCE Management Committee. Rationale and design of the AdRem study : Evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemporary Clinical Trials 2007 28:1:6-17.
Abstract
Perkovic V, Joshi R, Patel A, Bompoint S, Chalmers J on behalf of the ADVANCE Collaborative Group. ADVANCE: Lessons from the run-in phase of a large study in type 2 diabetes. Blood Press. 2006;15:340-346.
Abstract
Chalmers J, Perkovic V, Joshi R, Patel A. ADVANCE: Breaking new ground in type 2 diabetes. J.
Hypertens. 2006; 24 suppl 5): S22-S28.
Abstract
Patel A., Chalmers J. and Poulter N.. ADVANCE: action in diabetes and vascular disease. J. Hum. Hypertens. 2005;19:S27-S32.
Abstract
ADVANCE Collaborative Group. ADVANCE – Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study at baseline. Diabet. Med. 2005:22:882-888.
Abstract
Chalmers J. Nouvelles stratégies pour le contrôle de l’hypertension: preuves supplémentaries en faveur des associations faiblement dosées. (New Strategies for hypertension control : more evidence for low-dose combination therapy). A. J. Cardiovas. Drugs 2004; 4:1 :37-42.
Grobbee DE. How to ADVANCE prevention of cardiovascular complications in type 2 diabetes. Metabolism. 2003;52(Suppl 1):24
Abstract
Patel A., Chalmers J., Chaturvedi V. and al. Diabetes and Vascular disease – a New International Trial. Asian.Cardiovas. 2003;11:180-184.
Abstract
Chalmers J. Etude ADVANCE: objectifs, protocole et état actuel. Drugs. 2003; 63: 39-44.
Patel A, Chalmers J, Neal B, Chapman N, Girgis S, MacMahon S. Blood Pressure Lowering in Diabetes: a brief review of the current evidence and description of a new trial. Clini. Exp. Pharmacol. Physiol. 2001;28;1108-1111.
Abstract
ADVANCE Collaborative Group. Rationale and Design of the ADVANCE Study: A randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 diabetes. J. Hypertens. 2001;19 (Suppl 4):S21-S28.
Abstract
ADVANCE Management Committee. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation. Diabetologia. 2001;44:1118-1120.
Abstract
